Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is positioned for success in the pharmaceutical industry with their promising anti-VEGF treatment, TH103, set to enter the market in the early 2030s. With a potentially longer-lasting and safer treatment option, Kalaris is expected to capture a significant portion of the lucrative $15B market for VEGF-driven retinal diseases. Despite their strong intellectual property and strategic plans, Kalaris may encounter difficulties in commercialization if they are unable to expand their capabilities or secure additional funding. However, the positive results from clinical trials make Kalaris and their innovative treatment a strong contender in the competitive landscape of the pharmaceutical market.

Bears say

Kalaris Therapeutics is a biotechnology company with a promising drug in development for retinal diseases, but there are inherent risks in the sector. While TH103 has shown potential for extended benefits and differentiating itself from other branded drugs, the wet AMD market is dominated by these drugs and there are concerns about suboptimal treatment and alternative treatments being developed. The company is working on partnerships and improving their manufacturing process, which could lead to positive results, but a cautious approach is warranted when considering investing in biotechnology companies.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.